RecruitingPhase 4

Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Malaysia140 participantsStarted 2020-03-01

Plain-language summary

This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Malaysian citizens of who is able to give valid consent * Patient planned for ERCP (either emergency or elective) Exclusion Criteria: * Known hypersensitivity towards Ketamine or Midazolam * Patient refusal to participate or unable to give consent * Increased intracranial pressure, acute stroke (\<3 months), intracranial haemorrhage (\<3 months) * Uncontrolled hypertension (BP\>160/100) and tachycardia (Heart rate \>120) * Acute myocardial infarction, acute coronary syndrome (\<3 months) * Tachyarrythmia * Pregnancy * IVDU or substance abuse patient * Patient with history of hallucination * Child's Pugh Class C

What they're measuring

depth of sedation

Timeframe: 1 hour

completion rate

Timeframe: 1 hour

Trial details

NCT IDNCT04490031

SponsorUniversiti Kebangsaan Malaysia Medical Centre

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-31

Contact for this trial

Muhammad Hafiz Ismail, MBBS

6016 3354384 muhdhafizismail88@gmail.com

View on ClinicalTrials.gov More Ketamine Adverse Reaction trials